Innovotech Inc.
TSX VENTURE : IOT

Innovotech Inc.

May 20, 2009 14:22 ET

Innovotech Reports First Quarter 2009 Financial Results

EDMONTON, ALBERTA--(Marketwire - May 20, 2009) - Innovotech Inc. (TSX VENTURE:IOT) today announced its unaudited financial and operational results for the three month period ended March 31, 2009.

Highlights:

- 87% conversion of warrants further strengthens cash reserves to support product development

- Reduced revenue due to delays and postponement of research contracts

- Company business model proves its value during the current economic and financial crisis

"The improvement in cash reserves strengthens a product development effort that should result in product sales revenue in 2009 " said James Timourian, Chief Financial Officer of Innovotech. "While contract research revenue continues to be affected by the reduction in activity of small biotechnology companies, a broadened sales effort has led to an improved order book with larger clients in the second quarter. The company's focus on cash flow through contract research and developing innovative products with short regulatory pathways, such as the bioFILM PA™ kit and Agress™ seed treatment, is proving its value during the current financial crisis."




Financial Summary

Three month period ended Three month period ended
March 31, 2009 March 31, 2008

Revenues 216,000 428,286

G&A 246,036 241,777

R&D 192,150 103,406

Net Income (Loss) (367,269) (96,725)

Share Price $ .84 $ .90

Cash Reserves 2,210,484 2,139,507


About Innovotech Inc:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. The company currently has two products in advanced stages of development: bioFILM PA is a diagnostic kit which assists physicians in the selection of the most effective antibiotic treatment of patients with chronic lung infections. Agress™ is a novel seed treatment product which protects seeds during the critical germination and emergence stage from bacterial and fungal infection. Both products were developed against the corresponding organisms present as biofilms as opposed to the free-floating, planktonic form.

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information